Publication|Articles|December 1, 2025
Supplements and Featured Publications
- The Transformative Approach of TEVIMBRA® (tislelizumab-jsgr) in Managing ESCC and GC/GEJC
The Transformative Approach of TEVIMBRA® (tislelizumab-jsgr) in Managing ESCC and GC/GEJC
Advertisement
This Clinical Brief was sponsored by BeOne Medicines.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Real-World Data Show Most CRS, ICANS Cases Happen Within 15 Days of Liso-Cel Infusion
2
Real-World Usage of Nintedanib for PPF Differs From Trial Settings
3
NPM1 MRD Status Is a Dominant Predictor of AML Relapse After AlloHCT
4
Composite Inflammatory Index Linked to Elevated RA Risk
5









































